Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients

To the Editor

Source: Seminars in Hematology - June 17, 2016 Category: Hematology Authors: Pierre Peterlin, Thierry Guillaume, Jacques Delaunay, Mohamad Mohty, Alice Garnier, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Maud Voldoire, Cyrille Touzeau, Cecile Chauvin, Thomas Gastinne, Marie C Béné, Steven Le Gouill, Philippe Moreau, Patrice Tags: Letter to the Editor Source Type: research